133 related articles for article (PubMed ID: 21631585)
1. Physicochemical and biological aspects of macrophage-mediated drug targeting in anti-microbial therapy.
Kunjachan S; Jose S; Thomas CA; Joseph E; Kiessling F; Lammers T
Fundam Clin Pharmacol; 2012 Feb; 26(1):63-71. PubMed ID: 21631585
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of nanoparticulate systems for macrophage targeting.
Chellat F; Merhi Y; Moreau A; Yahia L
Biomaterials; 2005 Dec; 26(35):7260-75. PubMed ID: 16023200
[TBL] [Abstract][Full Text] [Related]
4. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
5. Drug delivery strategies for therapy of visceral leishmaniasis.
Gupta S; Pal A; Vyas SP
Expert Opin Drug Deliv; 2010 Mar; 7(3):371-402. PubMed ID: 20201740
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
7. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
9. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
Tempone AG; Mortara RA; de Andrade HF; Reimão JQ
Int J Antimicrob Agents; 2010 Aug; 36(2):159-63. PubMed ID: 20554161
[TBL] [Abstract][Full Text] [Related]
11. Delivery systems to increase the selectivity of antibiotics in phagocytic cells.
Briones E; Colino CI; Lanao JM
J Control Release; 2008 Feb; 125(3):210-27. PubMed ID: 18077047
[TBL] [Abstract][Full Text] [Related]
12. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome.
Patel B; Gupta N; Ahsan F
Eur J Pharm Biopharm; 2015 Jan; 89():163-74. PubMed ID: 25497488
[TBL] [Abstract][Full Text] [Related]
13. Nanotheranostics and image-guided drug delivery: current concepts and future directions.
Lammers T; Kiessling F; Hennink WE; Storm G
Mol Pharm; 2010 Dec; 7(6):1899-912. PubMed ID: 20822168
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis.
Nahar M; Dubey V; Mishra D; Mishra PK; Dube A; Jain NK
J Drug Target; 2010 Feb; 18(2):93-105. PubMed ID: 19640212
[TBL] [Abstract][Full Text] [Related]
15. The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking.
Matha K; Calvignac B; Gangneux JP; Benoit JP
Expert Opin Drug Deliv; 2021 Apr; 18(4):471-487. PubMed ID: 33217254
[No Abstract] [Full Text] [Related]
16. Inhibition of macrophage phagocytotic activity by a receptor-targeted polymer vesicle-based drug delivery formulation of pravastatin.
Broz P; Ben-Haim N; Grzelakowski M; Marsch S; Meier W; Hunziker P
J Cardiovasc Pharmacol; 2008 Mar; 51(3):246-52. PubMed ID: 18356688
[TBL] [Abstract][Full Text] [Related]
17. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles.
Venier-Julienne MC; Vouldoukis I; Monjour L; Benoit JP
J Drug Target; 1995; 3(1):23-9. PubMed ID: 7655817
[TBL] [Abstract][Full Text] [Related]
18. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis.
Kunjachan S; Gupta S; Dwivedi AK; Dube A; Chourasia MK
J Microencapsul; 2011; 28(4):301-10. PubMed ID: 21545321
[TBL] [Abstract][Full Text] [Related]
20. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis.
Mukherjee S; Das L; Kole L; Karmakar S; Datta N; Das PK
J Infect Dis; 2004 Mar; 189(6):1024-34. PubMed ID: 14999606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
